TMEM161A

Across TCGA pan-cancer cohorts, TMEM161A mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TMEM161A data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMEM161A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM161A expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

LUAD, UCEC, and PDAC are the cancer types where TMEM161A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.652	1.000	.008	5	view →
UCEC	DFS	Quartile	All	0.822	1.000	.028	4	view →
PDAC	OS	Median	III,IV	0.854	0.653	.026	3	view →
GBM	DFS	Median	All	0.461	0.296	.049	2	view →
CCRCC	DFS	Median	All	0.896	1.000	.029	1	view →
LSCC	OS	Median	All	0.800	1.000	.044	1	view →
HNSC	DFS	Median	III,IV	0.911	0.992	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TMEM161A–LUAD (DFS)

Open the LUAD breakdown →